A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

This study is testing a new oral pain medicine called iN1011-N17, which may help people with post-herpetic neuralgia — the persistent nerve pain that can linger after a shingles rash heals. Researchers want to understand how the drug moves through the body, whether it is safe, and whether it reduces pain. Healthy adults aged 18–55 and patients aged 50–75 with confirmed post-herpetic neuralgia lasting more than 3 months may be eligible to participate. Participation involves taking the study drug or a placebo by mouth over multiple days, with regular clinic visits for blood tests, vital sign checks, and pain assessments. This summary was generated by AI to help patients understand the study in plain language.